Skip to main content
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc — Investor Relations & Filings

Ticker · SNDX ISIN · US87164F1057 LEI · 529900OF94TRHKZVBS87 US Manufacturing
Open in API
Filings indexed 618 across all filing types
Latest filing 2024-05-15 Board/Management Inform…
Country US United States of America
Listing US SNDX

About Syndax Pharmaceuticals Inc

https://syndax.com/

Syndax Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes therapies for various cancers. The company focuses on developing first-in-class and best-in-class treatments for areas with significant unmet medical needs, such as acute leukemias and chronic Graft-versus-Host Disease (GVHD). Its pipeline targets a range of hematological malignancies and solid tumors, utilizing approaches in epigenetics and immunomodulation to create transformative therapies.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2024, which reports the election of a new director to the Board and the resignation of another director. It also includes the voting results from the company's annual meeting of stockholders held on May 15, 2024. The key content is about changes in the company's board of directors and the official voting results from the shareholder meeting. The document is not a full annual report, earnings release, or other financial report but rather a current report focusing on management changes and voting outcomes. Therefore, the document fits best under Board/Management Information (MANG) due to the director changes and also includes voting results, but since the voting results are part of the 8-K and not a standalone voting results announcement, the primary classification is MANG. Confidence is high given the clear SEC form type and content.
2024-05-15 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2024, by Syndax Pharmaceuticals, Inc. It announces the issuance of a press release containing financial results for the quarter and year ended March 31, 2024. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself does not contain detailed financial statements or substantive financial data. The length of the document is 3618 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the results themselves. Therefore, the appropriate classification is Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only.
2024-05-08 English
ARS
Annual Report
2024-04-02 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is identified as a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as "Definitive Additional Materials" related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is not a full annual report, earnings release, or other financial report but rather relates to shareholder voting and meeting information. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length is short and does not contain financial data, so it is not an Annual Report or Management Report. Confidence is high due to clear identification of the SEC form and purpose.
2024-04-02 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-02 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.